| Literature DB >> 32428007 |
Alexander Engels1, Katrin C Reber1, Ivonne Lindlbauer1, Kilian Rapp2, Gisela Büchele3, Jochen Klenk3, Andreas Meid4, Clemens Becker2, Hans-Helmut König1.
Abstract
OBJECTIVE: Hip fractures are among the most frequently occurring fragility fractures in older adults, associated with a loss of quality of life, high mortality, and high use of healthcare resources. The aim was to apply the superlearner method to predict osteoporotic hip fractures using administrative claims data and to compare its performance to established methods.Entities:
Year: 2020 PMID: 32428007 PMCID: PMC7237034 DOI: 10.1371/journal.pone.0232969
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of study population (n = 288,086).
| Characteristic | No. | % | ||
|---|---|---|---|---|
| Female gender | 140,709 | 48.8% | ||
| Age (at baseline), years | Mean (SD) | 75.67 | (6.20) | |
| Hip fracture within the 4 year follow-up | 7,644 | 2.7% | ||
| Patients without a hip fracture within the 4 year follow-up | 280,442 | 97.3% | ||
| Patients without a hip fracture within the 4 year follow-up who were not lost to follow-up | 231,578 | 80.4% | ||
| Prior osteoporotic fracture (2 years) | ||||
| all | 7,032 | 2.4% | ||
| minor | 2,580 | 0.9% | ||
| major | 4,864 | 1.7% | ||
| hip | 1,854 | 0.6% | ||
| Medication (within the seven months before baseline): | ||||
| Antiparkinson agents | 7,050 | 2.4% | ||
| Anticonvulsants/Antiepileptics | 8,313 | 2.9% | ||
| Aromatase inhibitors | 1,295 | 0.4% | ||
| Antidiabetic agents | 36,782 | 12.8% | ||
| Proton pump inhibitors | 55,770 | 19.4% | ||
| Antidementives | 2,509 | 0.9% | ||
| Drugs for obstructive airway diseases | 29,616 | 10.3% | ||
| Bisphosphonates | 9,451 | 3.3% | ||
| Bisphosphonate combinations | 1,831 | 0.6% | ||
| Raloxifene | 304 | 0.1% | ||
| Antidepressants, psycholeptics, and their combinations | 42,849 | 14.9% | ||
| Gestagens, estrogens, and their combinations | 10,030 | 3.5% | ||
| Glucocorticoids (systemic), and combinations with antiphlogistics/antirheumatics | 20,648 | 7.2% | ||
| Anti-inflammatory and antirheumatic agents | 2,299 | 0.8% | ||
| Calcium, vitamin D and analogues, and combinations | 9,798 | 3.4% | ||
| Thyreostatic agents | 3,632 | 1.3% | ||
| GnRH analogues, antiandrogens | 3,775 | 1.3% | ||
| Ophthalmic agents | 33,351 | 11.6% | ||
| Anticholinergic agents | 7,786 | 2.7% | ||
| Tamsulosin | 20,787 | 7.2% | ||
| Lost to follow-up: | ||||
| Total (death within four years, other reasons) | 51,476 | 17.9% | ||
| Death within the first year | 7,721 | 2.7% | ||
| Death within twoyears | 17,492 | 6.1% | ||
| Death within three years | 28,957 | 10.1% | ||
| Death within four years | 40,527 | 14.1% |
GnRH, Gonadotropin-releasing hormone.
Brier score and AUC for each algorithm.
| Validation | Training | ||||
|---|---|---|---|---|---|
| Algorithm | Brier score | AUC | (95% CI) | AUC | (95% CI) |
| Logistic regression with forward selection | 0.0251 | 0.704 | (0.691–0.718) | 0.713 | (0.705–0.720) |
| Logistic regression with forward selection and interactions | 0.0265 | 0.698 | (0.685–0.712) | 0.712 | (0.705–0.720) |
| Logistic regression with backward selection | 0.0261 | 0.704 | (0.690–0.717) | 0.713 | (0.705–0.720) |
| Logistic regression with backward selection and interactions | 0.0267 | 0.695 | (0.681–0.708) | 0.714 | (0.706–0.721) |
| Random forest | 0.0268 | 0.685 | (0.671–0.699) | 0.686 | (0.678–0.694) |
| Support vector machines | 0.0252 | 0.650 | (0.635–0.666) | 0.660 | (0.651–0.668) |
| RUSBoost | 0.0254 | 0.702 | (0.688–0.715) | 0.711 | (0.703–0.718) |
| Superlearner | 0.0259 | 0.698 | (0.684–0.711) | 0.722 | (0.714–0.729) |
| XGBoost | 0.0251 | 0.703 | (0.689–0.716) | 0.725 | (0.718–0.733) |
CI, confidence interval.
a) Brier score was calculated by transforming the support vector machine output to probabilities using a sigmoid link function.
Fig 1Calibration plots for logistic regression (left panel) and superlearner (right panel).
The plots show the calibration for the validation dataset. We grouped the n = 57,618 individuals in the validation dataset according to their respective 5% risk quantile as predicted by either the logistic regression or the superlearner. For each quantile group, we plotted the predicted proportion of S72.0-S72.2 fractures against the actual proportion of S72 fractures.
Coefficients of multivariable logistic regression to predict hip fracture.
| Predictor | β value | SE | p |
|---|---|---|---|
| Intercept | -9.216 | 0.204 | 0,000 |
| Age (effect for each additional year) | 0.101 | 0.003 | 0,000 |
| Female gender | 0.628 | 0.034 | 0,000 |
| Prior osteoporotic fracture (2 years) | 0.402 | 0.099 | 0,000 |
| Prior osteoporotic hip fracture (2 years) | 0.635 | 0.175 | 0,000 |
| Antidiabetic agents | 0.276 | 0.047 | 0,000 |
| Antiparkinson agents | 0.385 | 0.092 | 0,000 |
| Antidementives | 0.482 | 0.138 | 0,000 |
| Anticonvulsants/Antiepileptics | 0.270 | 0.087 | 0,002 |
| Proton pump inhibitors | 0.109 | 0.040 | 0,007 |
| Antidepressants, psycholeptics, and their combinations | 0.096 | 0.044 | 0,028 |
| Anticholinergic agents | 0.208 | 0.091 | 0,022 |
| Antiinflammatory and antirheumatic agents | 0.338 | 0.167 | 0,042 |
| Aromatase inhibitors | 0.319 | 0.218 | 0,144 |
| Thyreostatic agents | -0.182 | 0.130 | 0,159 |
| Glucocorticoids, and combinations with antiphlogistics/antirheumatics | 0.198 | 0.061 | 0,001 |
| GnRH analogues, antiandrogens | 0.338 | 0.125 | 0,007 |
| Gestagens, estrogens, and combinations | -0.244 | 0.091 | 0,008 |
| Bisphosphonates | 0.212 | 0.082 | 0,009 |
| Bisphosphonate combinations | 0.437 | 0.184 | 0,018 |
Results are based on the undersampled training dataset. Therefore, a meaningful interpretation can only be given for the effect direction and not the magnitude.
*** p ≤ 0.001
** p ≤ 0.01
* p ≤ 0.05. SE—standard error; GnRH—Gonadotropin-releasing hormone.